Important understandable point @NICU_Musings. This is the fundamental (too often repeated) problem of focusing research on unvalidated surrogate outcomes. Just as we showed that GMCSF increases WCC in growth restricted preterms but does not result in patient benefit (Lancet 2009)
Although darbepoetin for newborns 23-29 weeks increased RBCs and decreased transfusions sadly it didn’t translate into better neurodevelopmental outcomeView quoted post on X
The silver bullet remains elusive!
#neotwitter
jamanetwork.com/journals/jamap…